Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2255
Abstract: Introduction: Iberdomide (IBER) is an oral CELMoD™ agent with optimized cereblon binding leading to improved direct antitumor and immunostimulatory effects versus immunomodulatory drug (IMiD®) agents. Preliminary findings from the phase 1/2 CC-220-MM-001 trial (NCT02773030) demonstrated… read more here.
Keywords: 001 trial; mrd negativity; 220 001; mrd negative ... See more keywords